OUR TEAM MEMBERS
Chris Buyse was CFO at ThromboGenics NV from September 2006 until June 2014. He has 30 years of experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign. Before this, he was Finance Director of WorldCom/MCI Belux, and was CFO and interim CEO of Keyware Technologies, in addition, he held several financial positions at Suez Lyonnaise des Eaux and Unilever. He is currently serving as an independent Board Member of a few companies, mostly active in life sciences such as Celyad, Iteos and Bioxodes.
Philippe Monteyne holds an M.D. degree trained as a Neurologist and a Ph.D. in Viral Immunology, both at the UCL (Univ. Cathol. de Louvain), followed by a post-doctoral fellowship at Pasteur Institute, Paris. During the last 20 years, he held senior positions in top pharma companies such as SmithKline Beecham, GSK Biologicals (as Head of Global Vaccine Development) and GSK Rare Diseases (Head of Development and Chief Medical Officer) and SANOFI (Vice President R&D France). He is also currently member of different Strategic Advisory Committees. He is also visiting Professor of Neurology at the UCL.
Jan Van den Bossche
Jan Van den Bossche holds a Master Degree in Applied Economic Sciences at the KU Leuven. He worked for more than 12 years as a biotech analyst at Petercam. He was involved in numerous public and private transactions of Belgian and Dutch Biotech companies, such as ThromboGenics, Tigenix, UCB, AMT (Uniqure), IBA, MDxHealth . Before he joined Fund+, he was for more than 2 years part of the investor relations team at the Dutch life sciences and materials sciences company DSM (Geleen, NL).
Alexandra Tolia holds a Ph.D. in Medical Sciences from the KU Leuven, followed by a postdoctoral fellowship at UCSF, and an executive degree in General Management from the Solvay Brussels School of Economics and Management. Before joining Fund+, Alexandra led investments in private and public companies at PMV and Hunza Ventures, where she built strong Life sciences portfolios in Europe and the US. Alexandra is the author of high impact publications in the fields of neurodegeneration and cardiovascular disease and has served as board member in several companies active in biotech, diagnostics and medical technologies.
Louis is trained as an MD and Biomedical Engineer and very passionate about the Life Science industry. He has a specific interest in Biotechnology & Bio-electronics, Neuro-engineering and emerging Medical devices. In the process of being trained as a Neurosurgeon, Louis decided to stop this course of direction and pursued a Biomedical Engineering degree at Ghent University instead so he could contribute to the development and scale-up of new businesses in the Biomedical and Biotechnology industry. Most recently, Louis started an MBA at Warwick Business School (UK).
Caroline holds a Ph.D. in Pharmaceutical Sciences at KU Leuven followed by an MBA and an executive master in corporate finance, both from Vlerick Business School. She started her career at UCB taking on various roles ranging from commercial responsibilities (marketing and sales) to business development, portfolio management and R&D strategy. Fascinated by the intersection of research and commercialisation, she then joined Gimv where she focused on early stage biotech and medtech investment opportunities while driving portfolio value as a board member of companies in biotech (Complix) and diagnostics (Multiplicom).
Lawrence Van Helleputte
Lawrence holds a Ph.D. in Biomedical Sciences from the VIB-KU Leuven Centre of Brain & Disease Research. There, he focused on the pathophysiology underlying peripheral neuropathies which contributed to the successful creation of Augustine Therapeutics, a spin-off intended to give clinical answers to devastating neuromuscular and neurodegenerative disorders. After his academic passage, Lawrence made the transition to start-up biotech and worked for more than 3 years as a Senior Scientist at CoBioRes NV, converging the preclinical development of targeted anti-cancer therapies. His tremendous desire to work on the frontline of upcoming technologies and innovations directed him towards Fund+, where he recently joined as Scientific Investment Analyst.
Diane De Wyngaert
Diane holds a bachelor degree in informatics. She worked as administrative assistant and bookkeeper for several companies such as ADB (Siemens), VIB and Life Sciences Research Partners (still currently).